Laddar...
Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
Emicizumab, a humanized, bi-specific, monoclonal antibody subcutaneously administered, mimicking the function of FVIIIa, represents a milestone in treatment of patients affected by hemophilia A complicated with inhibitors. The HAVEN 1 and 2 studies have clearly established its superiority compared t...
Sparad:
| I publikationen: | Ther Clin Risk Manag |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7251291/ https://ncbi.nlm.nih.gov/pubmed/32547043 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S205310 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|